Boxer Capital Management LLC

-

Assets, Funds, Holdings

Home | Sign Up | Log In
New Features
Latest Fund Raises
Related People
Fund Service Providers
Startup & Company Raises
List of Funds
Boston Firms
Boston Hedge Funds
Cornell Alumni Firms
CalPERS Portfolio
NYSCRF Portfolio
User Guide
Regulatory AUM vs AUM
LP Portfolios
Related Firms
Build a Portfolio
Comprehensive Search
Keyboard
Boxer Capital Management LLC
CRD #330106
SEC #801-130351
CIK #0001465837, 0002018299
AUM 578.2 M (2026-05-11)
Employees 19 (42% Investors, 0% Brokers)
Fees
Minimum
Phone858-400-3115
Address12860 El Camino Real, Ste 300
San Diego, CA 92130
Source [IAPD] [EDGAR] [Website] [LinkedIn]
Total AUM ($B)
3.02.41.81.20.60.02010201520212027
Fees and Compensation — Form ADV Part 2A (3/31/2026) [Brochure]
Item 5: Fees and Compensation

Generally, BCM is compensated by the receipt of fees based on the value of the Advisory Client’s assets
under management (“Management Fees”) and/or the payment of certain performance-based
compensation (“Incentive Allocation”). In limited circumstances, BCM receives an agreed upon fixed
fee from certain Advisory Client(s).

Fund Fees and Compensation

As compensation for its advisory services to the Funds, in certain cases BCM receives an asset-based
Management Fee, typically equal to a percentage of up to 2% per annum of the net asset value of the
Funds’ assets, paid quarterly in advance based on the value of the net assets of the Funds on the last
business day of the prior quarter. Typically, BCM would return a pro-rata portion of any fees received in
advance if the advisory contract is terminated prior to the end of the billing period.

As a general matter, and in accordance with Funds’ Governing Documents, BCM, or its affiliates, may
receive performance-based compensation in the form of an Incentive Allocation equal to a percentage
of up to 20% of the appreciation in the net asset value of an investor’s capital account in the Fund (as
applicable).

Management fees and performance fees are deducted from each Fund’s assets and are not billed
separately.

In certain cases, some Funds may be charged an agreed-upon flat fee, not to exceed an established
maximum.

BCM, or its affiliates, in its sole discretion, may waive or modify the Incentive Allocation or Management
Fees for any Fund investor or any Advisory Client, subject to any applicable regulations and the Funds’
Governing Documents, including investors who are employees and/or affiliates of BCM. Additional
information regarding fees and compensation is described in the Funds’ Governing Documents (as
applicable). Prospective investors in the Funds should review the Governing Documents in detail before
making an investment.

Account Fees and Compensation

The fee schedule applicable to an Account will be contained in the applicable Investment Management
Agreement with BCM. Such compensation is subject to negotiation between BCM and each Account.
Such compensation may be deducted from the Account and billed separately as agreed upon between
the parties and set forth in their respective investment management agreements. As noted above, BCM
may waive or reduce fees, or perform services for no fees, for certain Accounts of employees and/or
affiliates of BCM and others in its complete discretion.

Expenses

Advisory Clients will incur brokerage and other transaction costs, see Section 12 of this brochure which
discusses brokerage.

Advisory Clients will incur other fees and expenses in connection with BCM’s advisory services. Each
Advisory Client will be responsible for certain costs and expenses as detailed in the Governing
Documents and/or Investment Management Agreement. Such costs and expenses may include, but are

Boxer Capital Management, LLC
Form ADV Part 2A

not limited to, (i) brokerage fees and commissions and other transaction costs and investment-related
expenses incurred in connection with a fund’s investment and trading activities, including, without
limitation, expenses related to sourcing, identifying, negotiating, structuring, monitoring, acquiring,
holding or selling investments, research and related travel expenses, the costs of any independent
accountants or other experts or consultants engaged by BCM in connection with specific investments
and expenses associated with unconsummated investments (e.g., “broken-deal” expenses); (ii) clearing
and settlement charges; (iii) custody charges and borrowing costs (including with respect to public
securities sold short and the payment of withdrawal proceeds); (iv) any interest, fees (including
commitment fees), and costs of fund-related borrowings (including borrowings related to positions held
on margin); (v) expenses and filing fees related to the ongoing offering of Interests; (vi) routine operational
costs such as printing and duplication expenses, legal, accounting, director services, bookkeeping,
recordkeeping, licensing fees and related support expenses for order and execution management
systems, treasury systems and/or risk management systems, shadow accounting expenses, including
licensing fees and expenses of managed services, auditing, consulting and other professional expenses,
administration (including the costs and expenses of an administrator, including additional fees for
ancillary services), clerical and tax preparation expenses; (vii) information technology expenses
associated with all aspects of a fund’s operations and research platforms used on a fund’s behalf
(including, without limitation, the costs associated with establishing and maintaining investor reporting
systems, and information technology and data security programs and other systems designed to manage
and control cyber security risk); (viii) its pro rata portion of any E&O, D&O, or any other form of insurance
related to a fund and its management and operations; (ix) exchange, board of trade or other trading or
execution facility membership or participation expenses; (x) market data, price quote data and other
data, including, but not limited to, research data and alternate data, newswire and data processing
expenses, cloud computing and cloud data storage fees and expenses, and connectivity charges; (xi)
fees and costs payable in connection with preparing and mailing reports to limited partners of a fund; (xii)
compliance related expenses and fees and expenses associated with preparing and submitting
regulatory filings required in respect of a fund (e.g., expenses relating to the preparation and filing of SEC
Form PF); (xiii) all other ordinary and out-of-pocket expenses of a fund and/or a related master fund; (xiv)
all taxes (if any) imposed on a fund and/or a related master fund (or that a fund and/or a related master
...
Account Minimums and Types of Clients — Form ADV Part 2A (3/31/2026) [Brochure]
Item 7: Types of Clients

As described in Item 4, BCM provides investment advisory services to Funds, Accounts and others it may
accept as clients from time to time in its discretion.

Investment in Funds sponsored by BCM will generally be limited to investors that meet the eligibility
qualifications of both (i) “accredited investors” within the meaning of Regulation D of the Securities Act
of 1933, as amended (“Accredited Investors”) and (ii) “qualified purchasers” within the meaning of
Section 2(a)(51) of the Investment Company Act of 1940, as amended. Such investors typically will be
institutional investors, financial institutions, other investment funds, and high-net-worth individuals,
each of whom make representations concerning their financial sophistication and ability to bear the risk
of loss respecting their investment in a Fund.

Accounts are typically only open to institutional investors, and BCM determines the minimum
investment amounts on a case-by-case basis. Typically, such Accounts involve significant minimum
investments.

The minimum initial investment amount in a Fund is disclosed in the respective Fund’s Governing
Documents, which will be provided to Fund investors and prospective investors and is subject to waiver
or modification at the discretion of BCM or its affiliates, subject to any applicable regulations.

Boxer Capital Management, LLC
Form ADV Part 2A
CIK Period
0001465837 0002018299
Sector Form 13F Holdings Value ($B)
BCTG Acquisition Corp 0.2
Kodiak Sciences Inc 0.1
Revolution Medicines Inc 0.0
Kymera Therapeutics Inc 0.0
Celcuity Inc 0.0
Consonance-HFW Acquisition Corp 0.0
Abivax Sa 0.0
Vaxcyte Inc 0.0
Nile Therapeutics Inc 0.0
Protagonist Therapeutics Inc 0.0
VIR Biotechnology Inc 0.0
Corvus Pharmaceuticals Inc 0.0
Praxis Precision Medicines Inc 0.0
PTC Therapeutics Inc 0.0
Intrexon Corp 0.0
MIND Medicine Mindmed Inc 0.0
Amylyx Pharmaceuticals Inc 0.0
Uniqure NV 0.0
Rexahn Pharmaceuticals Inc 0.0
Corcept Therapeutics Inc 0.0
UroGen Pharma Ltd 0.0
Replimune Group Inc 0.0
UNUM Therapeutics Inc 0.0
Neuralstem Inc 0.0
Glycomimetics Inc 0.0
Allogene Therapeutics Inc 0.0
Cytokinetics Inc 0.0
Contineum Therapeutics Inc 0.0
 
 
 
Prev | Page 1 | Next
Type Form D Funds Date Sold AUM
HF Boxer Capital Master Fund LP [2025-03-31] 60.2 M 450.5 M
Filed 2025-10-15 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $100,000 · Remaining Indefinite · Duration More than one year · Net Assets $50,000,001 - $100,000,000
HF Boxer Capital LLC 2024-10-11 127.7 M
AUM Breakdown Accounts AUM ($B)
By Client Type
(a) Individuals (other than high net worth individuals) 0 0.0
(b) Individuals (high net worth individuals) 0 0.0
(c) Banking or thrift institutions 0 0.0
(d) Investment companies 0 0.0
(e) Business development companies 0 0.0
(f) Pooled investment vehicles 4 0.6
(g) Pension and profit sharing plans 0 0.0
(h) Charitable organizations 0 0.0
(i) State or municipal government entities 0 0.0
(j) Other investment advisers 0 0.0
(k) Insurance companies 0 0.0
(l) Sovereign wealth funds and foreign official institutions 0 0.0
(m) Corporations or other businesses not listed above 0 0.0
(n) Other 0 0.0
Total 4 0.6
By Discretionary
Discretionary 4 0.6
Non-Discretionary 0 0.0
Total 4 0.6
By Non-United States Persons
Non-United States Persons 0.1
United States Persons 0.5
Total 4 0.6
Form D Directors Role # Filings # Firms 2011 - 2026
Aaron Davis Executive Officer 40 4
Christopher Fuglesang Executive Officer 7 2
Boxer Capital GP LLC Executive Officer 2 2
Siddarth Subramony Executive Officer 1 1
Daniel Effinger Promoter 1 1
EDGAR Form CIK 2011 - 2026
13F-HR [0001465837]
3 [0001465837]
4 [0001465837]
SC 13D [0001465837]
SC 13G [0001465837]
13F-HR [0002018299]
3 [0002018299]
4 [0002018299]
SC 13G [0002018299]
Form 13D/13G Filer Form 13D/13G Subject Filed
Boxer Capital Management LLC Q32 Bio Inc [2026-07-10]
Boxer Capital Management LLC Surrozen Inc/DE [2026-05-15]
Boxer Capital LLC Instil Bio Inc [2024-09-27]
Boxer Capital LLC Uniqure NV [2024-07-18]
Boxer Capital LLC Century Therapeutics Inc [2024-04-22]
Boxer Capital LLC Fate Therapeutics Inc [2024-02-12]
Boxer Capital LLC Nkarta Inc [2024-01-18]
Boxer Capital LLC Springworks Therapeutics Inc [2022-09-19]
Boxer Capital LLC TYRA Biosciences Inc [2021-09-24]
Boxer Capital LLC Elevation Oncology Inc [2021-07-09]
View All
Firm Profile (Form ADV)
Discretionary AUM$2.5B
ServesInstitutional
Fund TypesHedge Fund
LEI254900EDWZKUIJFQA680
Form 3/4/5 Subject 2011 - 2026
Davis Aaron I
Boxer Capital Management LLC
Tango Therapeutics Inc
Tyra Biosciences Inc
iTeos Therapeutics Inc
Lewis Joseph
Boxer Asset Management Inc
Boxer Capital LLC
MVA Investors LLC
Lockend Five LLC
View All
Insider Transaction (Form 3/4/5) Date Action Shares Price Value ($)
Tango Therapeutics Inc TNGX
Common Stock
2024-11-06 Sell 3,080,000 $3.14 9,671,200
Tango Therapeutics Inc TNGX
Common Stock
2024-10-25 Sell 633,000 $6.87 4,348,710
Tango Therapeutics Inc TNGX
Common Stock
2024-10-22 Sell 250,000 $6.78 1,695,000
Tango Therapeutics Inc TNGX
Common Stock
2024-10-21 Sell 625,000 $7.05 4,406,250
Tyra Biosciences Inc TYRA
Pre-Funded Warrant (right to purchase) · derivative
2024-10-18 Grant 2,000,000
Tyra Biosciences Inc TYRA
Common Stock
2024-10-18 Disposed to issuer 2,000,000
iTeos Therapeutics Inc ITOS
Common Stock
2024-05-10 Grant 1,142,857 $17.50 19,999,998
Tyra Biosciences Inc TYRA
Common Stock
2024-02-06 Grant 63,412 $13.01 824,990
Tyra Biosciences Inc TYRA
Warrant (right to purchase) · derivative
2024-02-06 Grant 705,280 $13.01 9,175,693
Mirati Therapeutics Inc MRTX
Common Stock
2024-01-23 Disposed to issuer 203,754
Mirati Therapeutics Inc MRTX
Common Stock
2024-01-23 Disposed to issuer 3,135,966
Mirati Therapeutics Inc MRTX
Common Stock
2024-01-23 Disposed to issuer 3,201,440
Mirati Therapeutics Inc MRTX
Common Stock
2024-01-23 Disposed to issuer 30,518
Mirati Therapeutics Inc MRTX
Common Stock
2024-01-23 Disposed to issuer 287,866
Mirati Therapeutics Inc MRTX
Warrant (right to purchase) · derivative
2024-01-23 Disposed to issuer 332,809
Mirati Therapeutics Inc MRTX
Warrant (right to purchase) · derivative
2024-01-23 Disposed to issuer 3,578,036
Mirati Therapeutics Inc MRTX
Warrant (right to purchase) · derivative
2024-01-23 Disposed to issuer 1,413,475
Tango Therapeutics Inc TNGX
Common Stock
2023-10-16 Buy 500,000 $6.84 3,420,000
Tango Therapeutics Inc TNGX
Common Stock
2023-10-13 Buy 750,000 $7.07 5,302,500
Tango Therapeutics Inc TNGX
Common Stock
2023-10-09 Sell 50,000 $9.91 495,500
showing 20 of 194 most recent transactions
Comparable Firms State AUM
Tensor Edge Capital LLC
MA 584.8 M
Praesidium Investment Management Company LLC
NY 582.9 M
Freshford Capital Management LLC
NY 581.8 M
Cello Capital Management LP
NY 577.2 M
Tabor Asset Management LP
NY 577.2 M
Birnam Oak Advisors LP
NY 577.0 M
Muddy Waters Capital LLC
TX 576.3 M
Western Standard LLC
CA 574.9 M
Untitled Investments LP
NY 574.0 M
Prevatt Capital Ltd
571.5 M
Terms | Privacy | Providers | Companies | Guide
tony@aum13f.com